'Free survival' diaporamas de présentation

1.41k views • 88 slides

Keeping Pace with Targeted Therapies in Lung Cancer Highlights from the ASCO 2006 Annual Meeting

Keeping Pace with Targeted Therapies in Lung Cancer Highlights from the ASCO 2006 Annual Meeting. Introduction. Overview of Targeted Therapies and Focus on Monoclonals. Karen Kelly, MD Professor of Medicine Department of Medical Oncology University of Colorado at Denver Aurora, Colorado.

1.09k views • 76 slides

GCIG Cervix Committee November 14, 2008

GCIG Cervix Committee November 14, 2008. Regimen I Paclitaxel 135 mg/m 2 IV d1 (24h) Cisplatin 50 mg/m 2 IV d2 Q21d to progression/toxicity. GOG 240 Schema. R A N D O M I Z E. Regimen II Paclitaxel 135 mg/m 2 IV d1 (24h) Cisplatin 50 mg/m 2 IV d2

1.12k views • 68 slides

Current perspectives on Lipodystrophy

Current perspectives on Lipodystrophy. Mike Youle Director of HIV Research Royal Free Centre for HIV Medicine London, UK. What is lipodystrophy?. Lipodystrophies are disorders characterised by loss of adipose tissue Two main types:

1.24k views • 55 slides

Leading the Way in Cardiovascular Regenerative Medicine

Leading the Way in Cardiovascular Regenerative Medicine. CV disease: US prevalence. Myocardial ischemia 37 million *. Heart failure 5 million. Acute MI 865,000/year. Chest Pain 4.2 million emergency visits/year 6.4 million outpatient visits/year. Peripheral vascular disease 8 million.

957 views • 54 slides

Timing of Surgery in Endocarditis

910 views • 41 slides

1.02k views • 40 slides

PLASMA CELL DYSCRASIAS

CLASSIFICATION. Monoclonal gammopathy of uncertain significance (MGUS) Idiopathic Associated with other diseases (autoimmune, infectious, non-heme cancer, etc) Plasma cell or lymphoid malignancy Waldenstrom's macroglobulinemia Other lymphoproliferative disorders Smoldering multiple myeloma

3.23k views • 40 slides

Sarcomas

Sarcomas. Perspectives and Background. Sarcomas: Themes. Sarcomas are a heterogeneous collection of diseases and families of diseases Individual diseases/families may be defined molecularly and a molecular derangement characterizes each tumor type (usually)

792 views • 37 slides

Sickle Cell Disease Part I & II

Sickle Cell Disease Part I & II. MR 8/7/09 J. Chen. Introduction. Sickle Cell Disease is a chronic hemolytic anemia- includes hemoglobin varients : SS SC S-beta thalassemia SO Arab SD Characterized by hemolysis , vascular occlusion, organ ischemia, end organ damage

1.02k views • 36 slides

Translational research in colorectal cancer

Translational research in colorectal cancer. Tim Maughan Professor of Cancer Studies Consultant Clinical Oncologist. Developing a clinical research network. The Wales Cancer Trials Network 1998-2006. 1998 5.3 Staff 415 Patients 2.8% in Trials. Wales Cancer Trials Network. 2003

729 views • 35 slides

V alsartan A ntihypertensive L ong-Term U se E valuation Results

V alsartan A ntihypertensive L ong-Term U se E valuation Results. Stevo Julius, MD, ScD Professor of Medicine and Physiology Frederick G. Huetwell Professor of Hypertension University of Michigan Health System Ann Arbor, Michigan, USA. VALUE: Primary Hypothesis.

715 views • 29 slides

Patient

Patient . 64 yo caucasian woman noted to have elevated LFTs on annual P.E. Felt well. US Liver: 9 cm mass in right lobe of liver Biopsy: Melanoma, high mitotic rate PMH: Melanoma in situ removed from scalp 14 years earlier. Patient. PMH: Htn, osteoporosis

435 views • 23 slides

Cancer Center Trials at St. Barnabas Medical Center

Cancer Center Trials at St. Barnabas Medical Center. Oncology clinical research at Saint Barnabas Medical Center (SBMC) is supported by a staff of three.

431 views • 19 slides

A Proposal for BMS-354825 (Dasatinib) in GIST

A Proposal for BMS-354825 (Dasatinib) in GIST. Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center. BMS-354825 (Dasatinib).

450 views • 16 slides

393 views • 13 slides

Cytotoxic Chemotherapy Produces Limited Benefit in Stage IV NSCLC

Cytotoxic Chemotherapy Produces Limited Benefit in Stage IV NSCLC. All recent randomized chemotherapy studies have similar results Median survival: 8 mo 1-y survival: 34% A paradigm shift is needed!. Cisplatin/paclitaxel. 100. Cisplatin/gemcitabine. Cisplatin/docetaxel. 80.

345 views • 10 slides

End-points utilized in breast cancer clinical trials - Discussion

Novartis Oncology. End-points utilized in breast cancer clinical trials - Discussion. Discussant - Arunava Chakravartty Stat4Onc Symposium , Hartford, CT Apr-26, 2019. Disclaimer.

256 views • 10 slides

ESMO 2011 Lung Cancer AVAPERL Study

ESMO 2011 Lung Cancer AVAPERL Study. Authors : Dr. Sunil V erma Date posted: September 28 th , 2011. AVAPERL. Background: There is evidence for the use of bevacizumab in combination with chemotherapy in the first line treatment of advanced non-small cell lung cancer.

393 views • 6 slides

SABCS 2011 BOLERO-2 Updated Results

SABCS 2011 BOLERO-2 Updated Results. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial Presented by Dr. Gabriel Hortobagyi. Reviewer: Dr. Sunil Verma Date posted: December 12 th , 2011. BACKGROUND.

274 views • 6 slides